Audited financial results for the quarter / year ended on March 31, 2026
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences reported audited FY2026 standalone revenue of Rs 131,515 million, up ~18.7% from Rs 110,764 million in FY2025. However, standalone PAT fell sharply to Rs 35,598 million from Rs 57,749 million — a decline of ~38%. This steep PAT fall is partly due to a one-time exceptional item of Rs 1,669 million (impairment of Zydus VTEC subsidiary plus New Labour Code impact of Rs 601 million) and a significant increase in other expenses including a large foreign exchange loss of Rs 12,287 million (net). Consolidated revenue stood at Rs 271,484 million. Auditors Deloitte issued an unmodified (clean) opinion on both standalone and consolidated results, with no going concern issues noted. The Board recommended a dividend of Re 1 per share (100%). The tax expense for FY2026 reflects remeasurement under section 115BAA, making year-on-year comparisons distorted.
Revenue grew solidly, but the sharp ~38% PAT decline despite clean audit opinion signals cost pressures, likely from forex losses and one-time charges. Investors should focus on underlying operational performance excluding these exceptional and FX items.